title: Molecular targets and targeted therapeutics in endometrial cancer.
abstract: OBJECTIVE
  Endometrial cancer is the most common gynaecological malignancy in the western world. Two clinicopathological subtypes are recognized: type I (endometrioid) and type II (nonendometrioid) carcinomas. This review describes the molecular alterations in endometrial cancer and how this knowledge is leading to the development of novel treatments in this area.
  
  
  RESULTS
  Molecularly targeted agents have entered clinical trials in endometrial cancer. So far, mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic agents appear promising and are being pursued further in addition to other targeted approaches.
  
  
  CONCLUSIONS
  The clinicopathological and molecular heterogeneity of endometrial cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer.
authors.affiliation: Cancer Research UK London Research Institute, London, UK.
authors.forename: Britta
authors.initials: B
authors.lastname: Weigelt
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents